Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca, Merck's Lynparza Prostate Cancer Study Meets Goal

AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.

BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies

BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255

Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.

AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review

Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed at $71.93 in the latest trading session, marking a +0.35% move from the prior day.

Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer

The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.

Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study

Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.

Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

The Zacks Analyst Blog Highlights: NVIDIA, Johnson & Johnson, Toyota, Merck and 3M

The Zacks Analyst Blog Highlights: NVIDIA, Johnson & Johnson, Toyota, Merck and 3M

Sheraz Mian headshot

Top Research Reports for NVIDIA, Johnson & Johnson & Toyota

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Johnson & Johnson (JNJ), and Toyota Motor Corporation (TM).

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study

Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) closed at $73.18 in the latest trading session, marking a -0.37% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Merck (MRK) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Merck (MRK) closed at $75.36, marking a -0.82% move from the previous day.

Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

Merck's (MRK) Keytruda Gets Nod for Expanded Use in China

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.

Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate

Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.

Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study

Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates

FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.